AI-DrivenAssetIncubator
Identify and incubate promising therapeutic assets towards a clinically meaningful inflection point - unlocking their full potential; positioning to be licensed out back to the industry. Our AI-driven approach enables strategic, capital-efficient development of high-value drug assets
What We Do
Partex.AI Therapeutics harnesses our proprietary AI platform to identify optimal therapeutic applications and clinical development pathways for in-licensed, off-strategy drug assets sourced from Pharma and Biotech. Through a data-driven strategy, we de-risk and reposition these compounds, advancing them toward clinically meaningful inflection points and unlocking their strategic commercial potential.
The portfolio companies are lean and agile and might range from incubator-style entities that benefit from close collaboration and centralized support through Partex.AI, to fully independent organizations with dedicated teams and governance, supported by external investors.
Portfolio
Partex.AI Therapeutics advances its assets through a focused portfolio structure, with compounds allocated to SPVs for targeted development. All oncology-related drug assets are consolidated within Oncoteq, our dedicated oncology vehicle, while additional portfolio companies still remain in stealth mode. Each entity is designed to provide focused development expertise and therapeutic depth, ensuring that every asset benefits from tailored scientific, clinical, and strategic capabilities.
Transforming Drug Development
Contact Us